Business
EyePoint and Rallybio Announce Research Collaboration to Evaluate Rallybio’s Inhibitor of Complement Component 5 (C5) and EyePoint’s Proprietary Durasert® Technology for Sustained Intraocular Delivery in Geographic Atrophy
WATERTOWN, Mass. & NEW HAVEN, Conn.--(BUSINESS WIRE)-- EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to
About this update from Eyepoint, Inc.
[{"type":"text","content":" WATERTOWN, Mass. & NEW HAVEN, Conn.--(BUSINESS WIRE)--\nEyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, and Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a research collaboration. The partnership will evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert® technology for sustained intraocular drug delivery. The initial focus will be on geographic atrophy, an advanced form of age-related macular degeneration that leads to irreversible vision loss.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230224005262/en/\n“We are excited to begin this research collaboration to explore the combination of Rallybio’s C5 inhibitor with our bioerodible Durasert sustained release drug delivery technology to develop a potential long-acting treatment for geographic atrophy,” said Jay Duker, M.D., President and Chief Operating Officer of EyePoint Pharmaceuticals. “Geographic atrophy associated with dry macular degeneration is a devastating eye disease, and the inhibition of complement is a proven treatment pathway. We hope to leverage our Durasert technology in this collaboration to create a potential best-in-class, long-acting intravitreal insert, which we believe could provide a more desirable option for patients given that the existing approved therapy is injected every one to two months.”\n\n“EyePoint’s proprietary Durasert sustained release technology combined with our differentiated C5 inhibitor offers the potential for a new, long-acting therapeutic for the treatment of eye diseases. Importantly, it’s a potential treatment option that requires less frequent intraocular injections with comparable efficacy that could provide a greatly improved alternative for patients. The use of C5 inhibitors for the treatment of eye disease has shown great promise, and we are excited to initiate this research in the hopes of improving the lives of patients suffering from eye diseases, such as geographic atrophy,” said Steve Uden, M.D., President ...